These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 9797217)

  • 1. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.
    Herreros E; Martinez CM; Almela MJ; Marriott MS; De Las Heras FG; Gargallo-Viola D
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2863-9. PubMed ID: 9797217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal activities and cytotoxicity studies of six new azasordarins.
    Herreros E; Almela MJ; Lozano S; Gomez de las Heras F; Gargallo-Viola D
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3132-9. PubMed ID: 11600368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
    Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
    Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
    J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of MICs of aminocandin for Candida spp. and filamentous fungi.
    Isham N; Ghannoum MA
    J Clin Microbiol; 2006 Dec; 44(12):4342-4. PubMed ID: 17021057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
    Zhanel GG; Karlowsky JA; Harding GA; Balko TV; Zelenitsky SA; Friesen M; Kabani A; Turik M; Hoban DJ
    Antimicrob Agents Chemother; 1997 Apr; 41(4):863-5. PubMed ID: 9087508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
    Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
    Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Tetz G; Collins M; Vikina D; Tetz V
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A head-on comparison of the in vitro antifungal activity of conventional and lipid-based amphotericin B: a multicenter study.
    Jessup C; Reyes G; Fothergill A; McCarthy D; Rinaldi M; Messer S; Pfaller M; Ghannoum M
    J Chemother; 2000 Feb; 12(1):22-9. PubMed ID: 10768512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.
    Ryder NS; Wagner S; Leitner I
    Antimicrob Agents Chemother; 1998 May; 42(5):1057-61. PubMed ID: 9593126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of a new oral triazole, BMS-207147 (ER-30346).
    Fung-Tomc JC; Huczko E; Minassian B; Bonner DP
    Antimicrob Agents Chemother; 1998 Feb; 42(2):313-8. PubMed ID: 9527778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro antifungal activity of anidulafungin].
    Quindós G; Eraso E
    Rev Iberoam Micol; 2008 Jun; 25(2):83-91. PubMed ID: 18473502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.
    Carrillo-Muñoz AJ; Ruesga M; Brio S; del Valle O; Rodriguez V; Santos P; Hernández-Molina JM; Cantón E; Pemán J; Guarro J; Quindós G
    Chemotherapy; 2002 Dec; 48(5):224-31. PubMed ID: 12476038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.